NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Salus BioMed

Salus BioMed

Private
ShenzhenHealthcare & Life Scienceshttps://www.salus-bio.com/

Last Round

Series B

Oct 10, 2025

Total Funding Raised

$20.92M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Salus BioMed is a life sciences company that provides a DNA sequencing platform and develops high-definition spatial transcriptomics to measure gene activity, aiding in the diagnosis and treatment of diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Data as a Service

AI Layer

Non-AI

Keywords

genetic sequencingnext-generation sequencingNGSspatial transcriptomicssequencing-by-synthesisSBSclinical diagnosticsprecision oncologygenomicsbenchtop sequencersequencing reagentsbioinformaticsrazor and bladesbiotech equipmentlab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Salus BioMed Comparables

Compare Salus BioMed with similar companies based on industry and business-model similarity.

Salus BioMed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Salus BioMed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 10, 2025
Series A ExtensionMay 14, 2025
Series ADec 1, 2023
SeedOct 18, 2022
AngelOct 1, 2021

Salus BioMed Investors

Notable investors and investment history

Salus BioMed investors
InvestorRounds
BioTrack CapitalSeries A
ZhenFundAngel
苏州敦行投资管理有限公司Series A
Qianhai Ark Asset ManagementSeries A
Shenzhen Capital GroupSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Grew 31% QoQ from 16 to 21 employees.

  • Apr 27, 2026

    Grew 33% QoQ from 15 to 20 employees.

Salus BioMed Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Salus BioMed Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Salus BioMed's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Employee Range22
Year Founded2020
Last FundingOct 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.